Kazia Therapeutics Advances Paxalisib with FDA Meeting

Kazia Therapeutics (KZIA) has released an update.

Kazia Therapeutics has announced a significant development in its quest to advance paxalisib, a promising treatment for newly diagnosed glioblastoma multiforme, as the FDA has agreed to a Type C meeting in December 2024 to discuss its potential registration pathways. The company also unveiled updates to its corporate presentation reflecting preliminary data from a recent Phase II/III trial, and plans to engage with investors at upcoming medical conferences, potentially boosting interest in its innovative cancer treatments.

For further insights into KZIA stock, check out TipRanks’ Stock Analysis page.